Skip to content

EPS (Basic) at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$3.37+32.7%
Veracyte logo
VeracyteVCYT
$0.36+300%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$0.29-61.1%
NeoGenomics logo
NeoGenomicsNEO
-$0.13+35.0%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$0.80-116%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$0.53-1.9%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's EPS (basic)?
Castle Biosciences (CSTL) reported EPS (basic) of -$0.49 in Q1 2026.
How has Castle Biosciences's EPS (basic) changed year-over-year?
Castle Biosciences's EPS (basic) increased by 45.6% year-over-year, from -$0.90 to -$0.49.
What is the long-term trend for Castle Biosciences's EPS (basic)?
Over 4 years (2021 to 2025), Castle Biosciences's EPS (basic) has grown at a -9.5% compound annual growth rate (CAGR), from -$1.24 to -$0.83.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.